Targeting an atypical G protein-coupled receptor signaling pathway for cardiac fibrosis therapy.
Through high-throughput screening, this work identified CGS15943 (CGS) as the lead antifibrotic compound and validated its activity in human cardiac fibroblasts, three-dimensional engineered heart tissues, and animal models of HF.